GlassScriptPhysician profile
Hillman Hum
NPI 1629105051
$26,627.28
in general payments reported to CMS, 2019-2025
31 companies · $3,158 in 2025
The $3,158 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,254 · 2020: $2,735 · 2021: $4,333 · 2022: $3,966 · 2023: $4,329 · 2024: $3,852 · 2025: $3,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,121.66 |
| Education | $216.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,570.27 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $3,928.20 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $3,924.62 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amgen INC. | $3,560.37 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $2,041.93 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $1,255.04 | 2019-2025 | |
| Novo Nordisk INC | $1,105.94 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $892.47 | 2020-2025 | Nexletol, Nexlizet |
| Amarin Pharma, INC. | $834.14 | 2019-2022 | |
| Ibsa Pharma INC. | $654.38 | 2020-2025 | Tirosint, Tirosint, Licart |
| Lilly USA, LLC | $630.74 | 2019-2025 | Jardiance, Emgality, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $470.87 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.65 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $357.33 | 2022 | |
| Merck Sharp & Dohme LLC | $284.87 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $266.98 | 2021 | |
| Allergan, INC. | $238.67 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $227.36 | 2019-2021 | |
| Exact Sciences Corporation | $186.34 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $178.75 | 2019-2022 | |
| Astellas Pharma US INC | $144.95 | 2020-2023 | Veozah |
| Genentech USA, INC. | $143.20 | 2019-2022 | |
| Pfizer INC. | $108.58 | 2020-2023 | |
| Nabriva Therapeutics, Plc | $63.41 | 2021-2022 | |
| Dexcom, INC. | $44.47 | 2024-2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $44.03 | 2020-2023 | Contrave |
| Edwards Lifesciences Corporation | $23.42 | 2020 | |
| Alk-Abello, INC | $18.65 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.21 | 2025 | Gvoke Hypopen |
| Lucid Diagnostics INC. | $14.77 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillman Hum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.